These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8641622

  • 1. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.
    Muggia FM, Liu PY, Alberts DS, Wallace DL, O'Toole RV, Terada KY, Franklin EW, Herrer GW, Goldberg DA, Hannigan EV.
    Gynecol Oncol; 1996 Jun; 61(3):395-402. PubMed ID: 8641622
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin).
    Muggia FM, Jeffers S, Muderspach L, Roman L, Rosales R, Groshen S, Safra T, Morrow CP.
    Gynecol Oncol; 1997 Aug; 66(2):290-4. PubMed ID: 9264578
    [Abstract] [Full Text] [Related]

  • 3. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
    Gadducci A, Iacconi P, Fanucchi A, Cosio S, Teti G, Genazzani AR.
    Anticancer Res; 2000 Aug; 20(3B):1959-64. PubMed ID: 10928134
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M.
    Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
    [Abstract] [Full Text] [Related]

  • 5. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R.
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [Abstract] [Full Text] [Related]

  • 6. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C, Louvet C, Molitor JL, Dehni N, Lejeune V, Sezeur A, Pigne A, Marpeau L, Cady J, de Gramont A.
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS.
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ, Braly P, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Najera L, Johnson D, Doroshow JH.
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [Abstract] [Full Text] [Related]

  • 9. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
    Tarraza HM, Boyce CR, Smith WG, Jones MA.
    Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
    [Abstract] [Full Text] [Related]

  • 10. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
    Berek JS, Markman M, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D.
    Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
    [Abstract] [Full Text] [Related]

  • 11. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, Bruzzone M, Conte PF.
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [Abstract] [Full Text] [Related]

  • 12. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T, Klasa-Mazurkiewicz D, Emerich J, Kobierski J.
    Acta Obstet Gynecol Scand; 2009 Feb; 88(4):463-7. PubMed ID: 19235559
    [Abstract] [Full Text] [Related]

  • 13. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
    Petit T, Velten M, d'Hombres A, Marchal C, Montbarbon X, Mornex F, Quetin P, Gérard JP, Romestaing P, Carrie C.
    Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
    [Abstract] [Full Text] [Related]

  • 14. Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study.
    Dufour P, Maloisel F, Bergerat JP, Barats JC, Dellenbach P, Renaud R, Ritter P, Herbrecht R, Wendling C, Audhuy B.
    Bull Cancer; 1991 Jan; 78(3):273-80. PubMed ID: 2054526
    [Abstract] [Full Text] [Related]

  • 15. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
    Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, Hanjani P.
    Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550
    [Abstract] [Full Text] [Related]

  • 16. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.
    Stiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh AR, Samlowski W, McCoy J, Alberts DS, Southwest Oncology Group Study.
    Gynecol Oncol; 2004 Jul; 94(1):98-106. PubMed ID: 15262126
    [Abstract] [Full Text] [Related]

  • 17. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
    Berek JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK.
    Obstet Gynecol; 1984 Aug; 64(2):207-12. PubMed ID: 6539884
    [Abstract] [Full Text] [Related]

  • 18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 19. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.
    Greer BE, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ.
    Gynecol Oncol; 2005 Oct; 99(1):71-9. PubMed ID: 16039699
    [Abstract] [Full Text] [Related]

  • 20. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA, Eisenhauer EL, Abu-Rustum NR, Venkatraman ES, Caceres A, Bier R, Huh J, Cho J, Barakat RR, Chi DS.
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.